Compounds for use in the treatment of filariasis

Abstract

A compound for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis of the general formula (1) or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of the general formula (1), a nematicidal composition comprising as an active ingredient a compound according to the general formula (1), and a method for treating filariasis.

What is claimed is: 
     
         1 - 10 . (canceled) 
     
     
         11 . A compound for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis of the general formula (1) 
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of the general formula (1), 
       wherein, 
       R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b): 
       
         
           
           
               
               
           
         
       
     
     
         12 . The compound as recited in  claim 11 , wherein the compound is the compound of formula (8a): 
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of the formula (8a). 
     
     
         13 . The compound as recited in  claim 11 , wherein the compound is the compound of formula (9a) 
       
         
           
           
               
               
           
         
       
       or at least one of solvates, hydrates, pharmaceutically acceptable salts, and esters of formula (9a). 
     
     
         14 . The compound as recited in  claim 11 , wherein the filariasis is selected from the group comprising lymphatic filariasis and onchocerciasis. 
     
     
         15 . The compound as recited in  claim 11 , wherein the filariasis is dirofilariasis. 
     
     
         16 . A pharmaceutical composition for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis, the pharmaceutical composition comprising, as an active ingredient, a compound of the general formula (1) 
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (1), 
       wherein, 
       R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b): 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         17 . The pharmaceutical composition as recited in  claim 16 , wherein the pharmaceutical composition is formulated for at least one of an oral application, a subcutaneous application, and an intravenous application. 
     
     
         18 . A pharmaceutical composition for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis, the pharmaceutical composition comprising:
 a pharmaceutically acceptable carrier; and   a compound of general formula (1)   
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (1), 
       wherein, 
       R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b): 
       
         
           
           
               
               
           
         
       
     
     
         19 . A method for a therapeutic treatment of filariasis or a prophylactic treatment of filariasis, the method comprising administering to a patient in need thereof an effective amount of a compound of the general formula (1) 
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (I), 
       wherein, 
       R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b): 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         20 . A method of treating filariasis or of prophylaxing filariasis, the method comprising:
 administering to a subject a therapeutically effective amount of a compound of the general formula (1)   
       
         
           
           
               
               
           
         
       
       or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (I), 
       wherein, 
       R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b):